Article

Moduladores alostéricos del receptor sensible al calcio e hiperparatiroidismo primario

Endocrinología y Nutrición 05/2008; 55(5). DOI: 10.1016/S1575-0922(08)70667-3
0 Followers
 · 
49 Views
  • Journal of Clinical Endocrinology &amp Metabolism 01/2003; 87(12):5353-61. DOI:10.1210/jc.2002-021370 · 6.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to investigate the risk of death among patients treated for primary hyperparathyroidism during the past decade. Using the national patient register, all patients operated on for primary hyperparathyroidism in Sweden during 1987-94 were identified and then searched for in the national register of deaths and causes of death during the same period. The control group was the whole Swedish population, matched for age, sex and calendar year. We found that patients treated for primary hyperparathyroidism run an increased risk of death. The risk ratios for death from cardiovascular disease were 1.71 for male and 1.85 for female patients. These estimations are of high precision because of the large patient series (n = 4461), with 95% confidence limits of 1.34-2.15 and 1.62-2.11 for men and women respectively. This finding, together with previous findings that parathyroid adenoma weight, serum calcium level and parathyroid hormone level are predictive of the risk of death, suggests the possibility that surgery in patients with primary hyperparathyroidism may offer not only relief from signs and symptoms but also improved prognosis.
    European Journal of Clinical Investigation 05/1998; 28(4):271-6. DOI:10.1046/j.1365-2362.1998.00289.x · 2.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary hyperparathyroidism is the most common cause of hypercalcemia in the outpatient setting and is typically caused by a single benign parathyroid adenoma. Most patients with hyperparathyroidism are postmenopausal women. Patients can be asymptomatic or minimally symptomatic. Parathyroidectomy is the definitive cure for primary hyperparathyroidism, and no medical therapies have been approved by the Food and Drug Administration for this disorder. Guidelines for surgery have been established by a National Institutes of Health consensus panel, but many patients do not meet these guidelines or have comorbid conditions that prohibit surgery. This review describes alternative treatment options for patients who decide against or are unable to proceed with surgery.
    Mayo Clinic Proceedings 04/2007; 82(3):351-5. DOI:10.4065/82.3.351 · 5.81 Impact Factor